- Champalimaud Foundation integrates Lonza’s MODA-ES® Platform to enhance cell therapy manufacturing.
- The platform aims to improve process transparency and expedite product release for cancer therapies.
Champalimaud Foundation, a biomedical clinical research organization, has implemented Lonza’s MODA-ES® Platform at its Clinical Centre in Lisbon, Portugal. This strategic move is set to streamline the manufacturing of cell therapies, particularly for patients with cancer who have unmet medical needs.
The installation of the MODA-ES® Platform is part of Champalimaud Foundation’s efforts to build a state-of-the-art GMP facility. This facility is dedicated to developing promising cell therapies under industrial standards. The foundation’s decision to adopt a paperless solution like MODA-ES® was driven by the need for enhanced safety in cell production, improved transparency for partners, and comprehensive monitoring of the production process—from reagent procurement to the final product release.
The Lonza MODA-ES® Platform is a configurable manufacturing execution system (MES) designed specifically for cell and gene therapy production. It consolidates manufacturing batch data and quality control information into a single record, reducing errors and expediting the release of therapeutic products. This system also ensures advanced traceability, supporting the integrity of the production process in decentralized cell and gene therapy manufacturing.
The Champalimaud Foundation’s immunotherapy team chose the MODA-ES® Platform due to Lonza’s proven expertise in e-solutions for cellular production. Orla Cloak, Senior Vice President and Head of Bioscience at Lonza, emphasized their commitment to helping customers bring innovative therapies to patients. Cloak stated, “We are proud to support our customers with an experienced implementation team that understands the intricacies of cell and gene therapy manufacture and can help to accelerate the path to market for these novel therapies.”
Overview of outsourcing trends 
